Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2'-deoxycoformycin. A new anticancer agent

D S Poster, J S Penta, S Bruno

    Cancer Clinical Trials
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach.

    Toxicology·2009
    Same author

    Home from home: residents' opinions of nursing homes and long-stay wards.

    Age and ageing·2005
    Same author

    Functional characterization of heme proteins encapsulated in wet nanoporous silica gels.

    Journal of nanoscience and nanotechnology·2003
    Same author

    Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
    Same author

    Safety and efficacy of laparoscopic radiofrequency ablation of hepatocellular carcinoma in patients with liver cirrhosis.

    Surgical endoscopy·2003
    Same journal

    Optimization of radiotherapy. Some notes on the principles and practice of optimization in cancer treatment and implications for clinical research.

    Cancer clinical trials·1981
    Same journal

    Statistical inference in the analysis of radiation compliance and its relation to treatment outcome.

    Cancer clinical trials·1981
    Same journal

    VP-16-213. A phase II trial using a weekly schedule.

    Cancer clinical trials·1981
    Same journal

    Phase I study of aziridinylbenzoquinone (NSC 182986).

    Cancer clinical trials·1981
    Same journal

    An alternative model for the evaluation of antitumor activity.

    Cancer clinical trials·1981
    Same journal

    A phase of I trial of 4'-epi-Adriamycin.

    Cancer clinical trials·1981
    See all related articles

    2'-deoxycoformycin (2'-dCF) inhibits adenosine deaminase (ADA) and shows clinical antitumor activity in lymphoid malignancies. Further trials are planned to explore its potential as a potentiator and immunosuppressive agent.

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Oncology

    Background:

    • Adenosine deaminase (ADA) is highly concentrated in lymphoid tissues.
    • 2 -deoxycoformycin (2 -dCF) is a potent ADA inhibitor.
    • ADA plays a role in deactivating certain antitumor agents.

    Purpose of the Study:

    • To evaluate the clinical antitumor activity of 2 -dCF.
    • To explore the potential of 2 -dCF as a potentiator of other chemotherapy drugs.
    • To investigate the immunosuppressive potential of 2 -dCF.

    Main Methods:

    • Phase I clinical studies are currently underway.
    • Phase II clinical trials are being planned.
    • Evaluation of 2 -dCF's efficacy in lymphoid malignancies.

    Related Experiment Videos

    Main Results:

    • 2 -dCF demonstrates clinical antitumor activity as a single agent in lymphoid malignancies.
    • Preclinical tumor models did not show activity for 2 -dCF.
    • ADA inhibition by 2 -dCF may enhance other antitumor agents.

    Conclusions:

    • 2 -dCF shows promise as a therapeutic agent for lymphoid malignancies.
    • Further research is warranted to define the full antitumor spectrum of 2 -dCF.
    • Potential applications include combination therapy and immunosuppression.